STOCK TITAN

Kyowa Kirin to end distribution of Fareston (toremefine) in the United States

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

Kyowa Kirin (TSE: 4151) has announced the discontinuation of Fareston (toremefine) 60 mg tablets distribution in the United States, effective August 31, 2024. This decision aligns with the company's Vision for 2030, focusing on novel therapies. The last order date is set for August 29, 2024, at 2:00 pm CT. Kyowa Kirin has notified the FDA and Orion , the manufacturer of toremefine tablets, about this change. For inquiries, stakeholders can contact specialty.channel.us@kyowakirin.com.

Kyowa Kirin (TSE: 4151) ha annunciato la cessazione della distribuzione delle compresse da 60 mg di Fareston (toremefine) negli Stati Uniti, efficace dal 31 agosto 2024. Questa decisione è in linea con la Visione per il 2030 dell'azienda, che si concentra su terapie innovative. La data ultima per gli ordini è fissata per il 29 agosto 2024 alle 14:00 CT. Kyowa Kirin ha informato la FDA e Orion, il produttore delle compresse di toremefine, riguardo a questo cambiamento. Per domande, le parti interessate possono contattare specialty.channel.us@kyowakirin.com.

Kyowa Kirin (TSE: 4151) ha anunciado la discontinuación de la distribución de tabletas de 60 mg de Fareston (toremefine) en los Estados Unidos, a partir del 31 de agosto de 2024. Esta decisión está en línea con la Visión para 2030 de la compañía, que se centra en terapias novedosas. La última fecha de pedidos está establecida para el 29 de agosto de 2024 a las 2:00 p. m. CT. Kyowa Kirin ha notificado a la FDA y a Orion, el fabricante de las tabletas de toremefine, sobre este cambio. Para consultas, los interesados pueden contactar a specialty.channel.us@kyowakirin.com.

교와 카린 (TSE: 4151)은 Fareston (토레메핀) 60mg 정제의 미국 내 유통 중단을 2024년 8월 31일부로 시행한다고 발표했습니다. 이 결정은 회사의 2030 비전과 일치하며, 혁신적인 치료법에 중점을 두고 있습니다. 주문 마감일2024년 8월 29일 오후 2:00 CT로 설정되어 있습니다. 교와 카린은 이 변경 사항에 대해 FDA와 토레메핀 정제의 제조사인 오리온에 통보했습니다. 문의 사항은 specialty.channel.us@kyowakirin.com으로 연락하시기 바랍니다.

Kyowa Kirin (TSE: 4151) a annoncé la cessation de la distribution des comprimés de 60 mg de Fareston (toremefine) aux États-Unis, à compter du 31 août 2024. Cette décision est conforme à la Vision 2030 de l'entreprise, qui se concentre sur des thérapies novatrices. La date limite de commande est fixée au 29 août 2024 à 14h00 CT. Kyowa Kirin a informé la FDA et Orion, le fabricant des comprimés de toremefine, de ce changement. Pour toute question, les parties intéressées peuvent contacter specialty.channel.us@kyowakirin.com.

Kyowa Kirin (TSE: 4151) hat die Einstellung der Verteilung von Fareston (Toremefin) 60 mg Tabletten in den Vereinigten Staaten zum 31. August 2024 bekannt gegeben. Diese Entscheidung steht im Einklang mit der Vision 2030 des Unternehmens, das sich auf neuartige Therapien konzentriert. Das letzte Bestelldatum ist auf den 29. August 2024 um 14:00 Uhr CT festgelegt. Kyowa Kirin hat die FDA und Orion, den Hersteller der Toremefin-Tabletten, über diese Änderung informiert. Bei Anfragen können Interessierte specialty.channel.us@kyowakirin.com kontaktieren.

Positive
  • Alignment with company's Vision for 2030
  • Strategic focus on novel therapies development
Negative
  • Discontinuation of Fareston distribution in the US market
  • Potential loss of revenue from Fareston sales

PRINCETON, N.J., Aug. 23, 2024 /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company based in Japan, is announcing that it will no longer distribute or fulfill orders for Fareston (toremefine) 60 mg tablets in the United States, effective August 31, 2024. This decision aligns with the company's Vision for 2030 and its focus on the discovery, development and delivery of novel therapies for patients. Kyowa Kirin has previously taken steps to notify the Food and Drug Administration (FDA) and the manufacturer of toremefine tablets, Orion Corporation, of these plans.

The last day for order placement will be August 29th, 2024, 2:00pm CT. Questions may be referred to specialty.channel.us@kyowakirin.com

About Kyowa Kirin 
Kyowa Kirin aims to discover and deliver novel treatments with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients with high unmet medical needs, focusing on bone/mineral, intractable hematological diseases/hemato oncology, and rare diseases. A shared commitment to our values, to sustainable growth, and to making people smile unites us across the globe.

You can learn more about the business of Kyowa Kirin at: www.kyowakirin.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/kyowa-kirin-to-end-distribution-of-fareston-toremefine-in-the-united-states-302229571.html

SOURCE Kyowa Kirin

FAQ

When will Kyowa Kirin stop distributing Fareston in the US?

Kyowa Kirin will stop distributing Fareston (toremefine) 60 mg tablets in the United States effective August 31, 2024.

What is the last date to place orders for Fareston from Kyowa Kirin?

The last day for order placement of Fareston from Kyowa Kirin is August 29, 2024, at 2:00 pm CT.

Why is Kyowa Kirin (KYKOY) discontinuing Fareston distribution?

Kyowa Kirin is discontinuing Fareston distribution to align with its Vision for 2030 and focus on the discovery, development, and delivery of novel therapies for patients.

Who is the manufacturer of Fareston (toremefine) tablets?

The manufacturer of Fareston (toremefine) tablets is Orion

KYOWA HAKKO KOGY UNSP/ADR

OTC:KYKOY

KYKOY Rankings

KYKOY Latest News

KYKOY Stock Data

8.94B
220.33M
Drug Manufacturers - General
Healthcare
Link
United States of America
Tokyo